Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations

Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial carcinoma patients. However, a substantial proportion of these patients (up to 50%) display intrinsic...

Full description

Bibliographic Details
Main Authors: Nadia Carvalho Lima, Eliza Atkinson, Tom D. Bunney, Matilda Katan, Paul H. Huang
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:International Journal of Molecular Sciences
Subjects:
FGFR3
Src
urothelial cancer
bladder cancer
cell signalling
cancer therapeutics
Online Access:https://www.mdpi.com/1422-0067/21/9/3214

Internet

https://www.mdpi.com/1422-0067/21/9/3214

Similar Items